Identification of stromal proteins overexpressed in nodular sclerosis Hodgkin lymphoma

Proteome Science

Research

Laurence de Leval¹  Gabriel Mazzucchelli²  Edwin De Pauw²  Yannick Greffe³  Philippe Kischel³  David Waltregny³  Vincent Castronovo³ 

[1] Department of Pathology, University Hospital of Liege, Bat. B23, CHU Sart Tilman Liège, B-4000, Liege, Belgium;Laboratory of Mass Spectrometry, Department of Chemistry, University of Liege, Bat. B6c, B-4000, Liège, Belgium;Metastasis Research Laboratory, GIGA Cancer, University of Liege, Bat. B23, CHU Sart Tilman Liège, B-4000, Liège, Belgium;

关键词: Biomarker discovery;    Lymphoma;    Mass spectrometry;    Tumour targeting;   

DOI  :  10.1186/1477-5956-9-63

 received in 2011-05-13, accepted in 2011-10-05,  发布年份 2011

来源: Springer

【 摘 要 】

Hodgkin lymphoma (HL) represents a category of lymphoid neoplasms with unique features, notably the usual scarcity of tumour cells in involved tissues. The most common subtype of classical HL, nodular sclerosis HL, characteristically comprises abundant fibrous tissue stroma. Little information is available about the protein composition of the stromal environment from HL. Moreover, the identification of valid protein targets, specifically and abundantly expressed in HL, would be of utmost importance for targeted therapies and imaging, yet the biomarkers must necessarily be accessible from the bloodstream. To characterize HL stroma and to identify potentially accessible proteins, we used a chemical proteomic approach, consisting in the labelling of accessible proteins and their subsequent purification and identification by mass spectrometry. We performed an analysis of potentially accessible proteins in lymph node biopsies from HL and reactive lymphoid tissues, and in total, more than 1400 proteins were identified in 7 samples. We have identified several extracellular matrix proteins overexpressed in HL, such as versican, fibulin-1, periostin, and other proteins such as S100-A8. These proteins were validated by immunohistochemistry on a larger series of biopsy samples, and bear the potential to become targets for antibody-based anti-cancer therapies.

【 授权许可】

Unknown   
© Kischel et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.